论文部分内容阅读
目的观察硫普罗宁干预治疗化疗引起的白细胞减少及肝功能损伤的临床疗效。方法选取2010.1～2012.1期间在本院血液科接受治疗的90例确诊并需执行全身化疗或灌注化疗的患者为研究对象,采取硫普罗宁干预治疗的45例为实验组,未采用硫普罗宁干预治疗的45例为对照组,回顾性分析和比较两组手术方法的疗效。结果两组白细胞减少程度经秩和检验,z=-3.464,p=0.001,P<0.05,提示组间白细胞减少率比较存在显著差异性。实验组干预治疗后ALP、TBIL及DBIL下降最为显著,P<0.01,ALT、AST下降差异有显著性,P<0.05,提示比较有统计学意义。结论硫普罗宁干预治疗化疗引起的白细胞减少和肝功能损伤有较好的效果,值得临床推广应用。
Objective To observe the clinical efficacy of tiopronin in the treatment of chemotherapy-induced leukopenia and liver injury. Methods Totally 90 patients diagnosed with systemic chemotherapy or chemotherapy in our department of hematology from 2010.1 to 2012.1 were enrolled in this study. Forty-five patients treated with tiopronin were selected as experimental group without intervention of tiopronin 45 cases of treatment for the control group, a retrospective analysis and comparison of the efficacy of the two surgical methods. Results The degree of leukopenia in both groups was determined by rank sum test, z = -3.464, p = 0.001, P <0.05, suggesting that there was a significant difference in leukopenia between the two groups. The decrease of ALP, TBIL and DBIL in the experimental group was the most significant, P <0.01, the difference of ALT and AST was significant difference (P <0.05), suggesting that there was statistical significance. Conclusion The intervention of tiopronin in the treatment of chemotherapy-induced leukopenia and liver damage have a good effect, worthy of clinical application.